IndiaThe Maharashtra Food and Drug Administration (FDA) has revoked the drug sale licenses of Cipla Pharma & Life Sciences Ltd’s Carry and Forwarding (C&F) facility in Pune due to regulatory violations. The action, effective August 27, followed an inspection that uncovered unauthorized promotional text on the packaging of Reactin Plus, a Schedule H prescription medicine. The FDA seized stock valued at ₹11.19 lakh and mandated a recall, citing breaches of the Drugs and Cosmetics Act, 1940, and Rules, 1945. Additional irregularities were found in storage, distribution, and record-keeping practices. FDA Commissioner Tukaram Mundhe emphasized the importance of strict compliance with legal standards to ensure drug safety and public health.
Bias read (Center): The article presents a factual account of regulatory enforcement actions against a pharmaceutical company, focusing on compliance issues and public health concerns. There is no overt ideological framing or emphasis on political agendas. The tone remains objective, detailing the FDA's findings and affi
